Now, the FDA has added three new products to its list of medicines in short supply as a result of the plant being taken ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

Sanofi said in October last year that it was planning to spin off its consumer health business into a separate company before ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...

The consultation on raising the threshold suggests that this change will “ensure that the BIT continues to target those ...

Artificial intelligence (AI) is an increasingly valuable tool in our perpetual quest for the miracles that science regularly ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

The landscape of medical technology start-ups is undoubtedly poised for significant evolution due to the FDA’s final rule.

The way forward, then, is to deliver truly personalised medicines and care. For industry, this means developing therapies ...